Inhibrx Biosciences (INBX) Competitors

$128.12 +0.17 (+0.13%)

Closing price 04:00 PM Eastern

Extended Trading

$128.18 +0.06 (+0.05%)

As of 04:10 PM Eastern

INBX vs. CYTK, IBRX, QGEN, KYMR, and ACLX

Should you be buying Inhibrx Biosciences stock or one of its competitors? The main competitors of Inhibrx Biosciences include Cytokinetics (CYTK), ImmunityBio (IBRX), Qiagen (QGEN), Kymera Therapeutics (KYMR), and Arcellx (ACLX). These companies are all part of the "pharmaceutical products" industry.

How does Inhibrx Biosciences compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and Inhibrx Biosciences (NASDAQ:INBX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

: Cytokinetics has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500. Comparatively, Inhibrx Biosciences has a beta of 3.88, meaning that its stock price is 288% more volatile than the S&P 500.
: In the previous week, Cytokinetics had 25 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 30 mentions for Cytokinetics and 5 mentions for Inhibrx Biosciences. Cytokinetics' average media sentiment score of 0.49 beat Inhibrx Biosciences' score of 0.28 indicating that Cytokinetics is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cytokinetics
13 Very Positive mention(s)
3 Positive mention(s)
9 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Inhibrx Biosciences
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Inhibrx Biosciences has lower revenue, but higher earnings than Cytokinetics. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cytokinetics $88.04M 108.79 -$784.96M -$6.53 N/A
Inhibrx Biosciences $1.30M 1,439.58 -$140.05M -$9.04 N/A
: Cytokinetics currently has a consensus target price of $92.10, suggesting a potential upside of 19.47%. Inhibrx Biosciences has a consensus target price of $150.00, suggesting a potential upside of 17.08%. Given Cytokinetics' stronger consensus rating and higher possible upside, research analysts clearly believe Cytokinetics is more favorable than Inhibrx Biosciences.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cytokinetics
1 Sell rating(s)
3 Hold rating(s)

17 Buy rating(s)

1 Strong Buy rating(s)
2.82
Inhibrx Biosciences
1 Sell rating(s)

3 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.33
: Inhibrx Biosciences has a net margin of 0.00% compared to Cytokinetics' net margin of -891.60%. Cytokinetics' return on equity of 0.00% beat Inhibrx Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Cytokinetics -891.60% N/A -49.62%
Inhibrx Biosciences N/A -269.56% -71.94%
: 82.5% of Inhibrx Biosciences shares are held by institutional investors. 2.6% of Cytokinetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	13 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inhibrx Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	108.79	-$784.96M	-$6.53	N/A
Inhibrx Biosciences	$1.30M	1,439.58	-$140.05M	-$9.04	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.82
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-891.60%	N/A	-49.62%
Inhibrx Biosciences	N/A	-269.56%	-71.94%

Summary

Cytokinetics beats Inhibrx Biosciences on 11 of the 16 factors compared between the two stocks.

How does Inhibrx Biosciences compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Inhibrx Biosciences (NASDAQ:INBX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

: ImmunityBio has a beta of 0.02, meaning that its stock price is 98% less volatile than the S&P 500. Comparatively, Inhibrx Biosciences has a beta of 3.88, meaning that its stock price is 288% more volatile than the S&P 500.
: In the previous week, ImmunityBio had 31 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 36 mentions for ImmunityBio and 5 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 0.28 beat ImmunityBio's score of 0.04 indicating that Inhibrx Biosciences is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ImmunityBio
0 Very Positive mention(s)
1 Positive mention(s)
34 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Inhibrx Biosciences
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: 8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are held by institutional investors. 69.5% of ImmunityBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
: Inhibrx Biosciences has lower revenue, but higher earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ImmunityBio $113.29M 68.79 -$351.40M -$0.38 N/A
Inhibrx Biosciences $1.30M 1,439.58 -$140.05M -$9.04 N/A
: Inhibrx Biosciences has a net margin of 0.00% compared to ImmunityBio's net margin of -310.18%. ImmunityBio's return on equity of 0.00% beat Inhibrx Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
ImmunityBio -310.18% N/A -81.40%
Inhibrx Biosciences N/A -269.56% -71.94%
: ImmunityBio currently has a consensus target price of $14.40, suggesting a potential upside of 89.97%. Inhibrx Biosciences has a consensus target price of $150.00, suggesting a potential upside of 17.08%. Given ImmunityBio's stronger consensus rating and higher possible upside, research analysts clearly believe ImmunityBio is more favorable than Inhibrx Biosciences.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImmunityBio
1 Sell rating(s)
0 Hold rating(s)

5 Buy rating(s)

1 Strong Buy rating(s)
2.86
Inhibrx Biosciences
1 Sell rating(s)

3 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.33

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	0 Very Positive mention(s)	1 Positive mention(s)	34 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Inhibrx Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	68.79	-$351.40M	-$0.38	N/A
Inhibrx Biosciences	$1.30M	1,439.58	-$140.05M	-$9.04	N/A

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-310.18%	N/A	-81.40%
Inhibrx Biosciences	N/A	-269.56%	-71.94%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

Summary

ImmunityBio and Inhibrx Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Inhibrx Biosciences compare to Qiagen?

Qiagen (NYSE:QGEN) and Inhibrx Biosciences (NASDAQ:INBX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings.

: Qiagen has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, Inhibrx Biosciences has a beta of 3.88, meaning that its stock price is 288% more volatile than the S&P 500.
: In the previous week, Qiagen had 19 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 24 mentions for Qiagen and 5 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 0.28 beat Qiagen's score of 0.18 indicating that Inhibrx Biosciences is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Qiagen
4 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
3 Negative mention(s)
3 Very Negative mention(s)
Neutral
Inhibrx Biosciences
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: 70.0% of Qiagen shares are held by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are held by institutional investors. 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
: Qiagen has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Qiagen $2.09B 3.35 $424.88M $2.02 16.82
Inhibrx Biosciences $1.30M 1,439.58 -$140.05M -$9.04 N/A
: Qiagen has a net margin of 20.33% compared to Inhibrx Biosciences' net margin of 0.00%. Qiagen's return on equity of 14.56% beat Inhibrx Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Qiagen 20.33% 14.56% 8.62%
Inhibrx Biosciences N/A -269.56% -71.94%
: Qiagen currently has a consensus target price of $47.09, suggesting a potential upside of 38.56%. Inhibrx Biosciences has a consensus target price of $150.00, suggesting a potential upside of 17.08%. Given Qiagen's stronger consensus rating and higher probable upside, equities analysts clearly believe Qiagen is more favorable than Inhibrx Biosciences.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qiagen
0 Sell rating(s)
7 Hold rating(s)

4 Buy rating(s)

1 Strong Buy rating(s)
2.50
Inhibrx Biosciences
1 Sell rating(s)

3 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.33

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	4 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	3 Very Negative mention(s)	Neutral
Inhibrx Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	3.35	$424.88M	$2.02	16.82
Inhibrx Biosciences	$1.30M	1,439.58	-$140.05M	-$9.04	N/A

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	20.33%	14.56%	8.62%
Inhibrx Biosciences	N/A	-269.56%	-71.94%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	0 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

Summary

Qiagen beats Inhibrx Biosciences on 12 of the 16 factors compared between the two stocks.

How does Inhibrx Biosciences compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Inhibrx Biosciences (NASDAQ:INBX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings.

: In the previous week, Kymera Therapeutics had 21 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 26 mentions for Kymera Therapeutics and 5 mentions for Inhibrx Biosciences. Kymera Therapeutics' average media sentiment score of 0.38 beat Inhibrx Biosciences' score of 0.28 indicating that Kymera Therapeutics is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kymera Therapeutics
4 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Inhibrx Biosciences
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Kymera Therapeutics has a beta of 2.06, meaning that its stock price is 106% more volatile than the S&P 500. Comparatively, Inhibrx Biosciences has a beta of 3.88, meaning that its stock price is 288% more volatile than the S&P 500.
: Inhibrx Biosciences has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Inhibrx Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Kymera Therapeutics -611.94% -24.71% -22.05%
Inhibrx Biosciences N/A -269.56% -71.94%
: Kymera Therapeutics currently has a consensus target price of $118.70, suggesting a potential upside of 43.51%. Inhibrx Biosciences has a consensus target price of $150.00, suggesting a potential upside of 17.08%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Kymera Therapeutics is more favorable than Inhibrx Biosciences.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kymera Therapeutics
1 Sell rating(s)
0 Hold rating(s)

20 Buy rating(s)

1 Strong Buy rating(s)
2.95
Inhibrx Biosciences
1 Sell rating(s)

3 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.33
: 82.5% of Inhibrx Biosciences shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
: Inhibrx Biosciences has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kymera Therapeutics $51.48M 132.17 -$311.35M -$3.57 N/A
Inhibrx Biosciences $1.30M 1,439.58 -$140.05M -$9.04 N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inhibrx Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Inhibrx Biosciences	N/A	-269.56%	-71.94%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.95
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$51.48M	132.17	-$311.35M	-$3.57	N/A
Inhibrx Biosciences	$1.30M	1,439.58	-$140.05M	-$9.04	N/A

Summary

Kymera Therapeutics beats Inhibrx Biosciences on 10 of the 16 factors compared between the two stocks.

How does Inhibrx Biosciences compare to Arcellx?

Inhibrx Biosciences (NASDAQ:INBX) and Arcellx (NASDAQ:ACLX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

: In the previous week, Arcellx had 6 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 11 mentions for Arcellx and 5 mentions for Inhibrx Biosciences. Arcellx's average media sentiment score of 0.65 beat Inhibrx Biosciences' score of 0.28 indicating that Arcellx is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Inhibrx Biosciences
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Arcellx
3 Very Positive mention(s)
5 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Inhibrx Biosciences has a beta of 3.88, suggesting that its stock price is 288% more volatile than the S&P 500. Comparatively, Arcellx has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500.
: Inhibrx Biosciences has a net margin of 0.00% compared to Arcellx's net margin of -1,027.26%. Arcellx's return on equity of -55.42% beat Inhibrx Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Inhibrx Biosciences N/A -269.56% -71.94%
Arcellx -1,027.26% -55.42% -36.24%
: Inhibrx Biosciences presently has a consensus target price of $150.00, suggesting a potential upside of 17.08%. Arcellx has a consensus target price of $111.87, suggesting a potential downside of 2.78%. Given Inhibrx Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Inhibrx Biosciences is more favorable than Arcellx.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inhibrx Biosciences
1 Sell rating(s)
3 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.33
Arcellx
1 Sell rating(s)

16 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.11
: 82.5% of Inhibrx Biosciences shares are owned by institutional investors. Comparatively, 96.0% of Arcellx shares are owned by institutional investors. 8.4% of Arcellx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
: Inhibrx Biosciences has higher earnings, but lower revenue than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Inhibrx Biosciences $1.30M 1,439.58 -$140.05M -$9.04 N/A
Arcellx $22.29M 301.95 -$228.93M -$4.07 N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcellx	3 Very Positive mention(s)	5 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-269.56%	-71.94%
Arcellx	-1,027.26%	-55.42%	-36.24%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
Arcellx	1 Sell rating(s)	16 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.11

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	1,439.58	-$140.05M	-$9.04	N/A
Arcellx	$22.29M	301.95	-$228.93M	-$4.07	N/A

Summary

Arcellx beats Inhibrx Biosciences on 8 of the 15 factors compared between the two stocks.

Get Inhibrx Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INBX vs. The Competition

Export

Metric	Inhibrx Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.87B	$3.39B	$6.25B	$11.87B
Dividend Yield	N/A	2.20%	2.73%	5.21%
P/E Ratio	-14.17	38.92	29.03	28.47
Price / Sales	1,439.58	154.75	476.10	60.92
Price / Cash	N/A	57.88	27.62	36.52
Price / Book	232.95	7.03	9.67	6.67
Net Income	-$140.05M	$23.62M	$3.55B	$332.53M
7 Day Performance	-1.94%	3.78%	1.75%	2.03%
1 Month Performance	101.67%	7.30%	5.66%	9.23%
1 Year Performance	939.09%	67.15%	34.42%	39.62%

Inhibrx Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INBX Inhibrx Biosciences	1.696 of 5 stars	$128.12 +0.1%	$150.00 +17.1%	N/A	$1.87B	$1.30M	N/A	166	Analyst Upgrade
CYTK Cytokinetics	2.522 of 5 stars	$60.69 -1.5%	$90.55 +49.2%	N/A	$7.54B	$88.04M	N/A	250	Trending News Analyst Forecast Insider Trade Gap Up
IBRX ImmunityBio	2.8062 of 5 stars	$6.96 -4.5%	$14.40 +106.9%	N/A	$7.16B	$113.29M	N/A	590	Trending News Upcoming Earnings
QGEN Qiagen	4.5561 of 5 stars	$33.98 -10.8%	$53.64 +57.9%	N/A	$7.00B	$2.09B	16.85	5,654	Upcoming Earnings High Trading Volume
KYMR Kymera Therapeutics	2.9407 of 5 stars	$83.85 -3.3%	$118.90 +41.8%	N/A	$6.85B	$39.21M	N/A	170	Trending News Earnings Report Analyst Upgrade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INBX) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inhibrx Biosciences (INBX) Competitors

INBX vs. CYTK, IBRX, QGEN, KYMR, and ACLX

How does Inhibrx Biosciences compare to Cytokinetics?

Summary

How does Inhibrx Biosciences compare to ImmunityBio?

Summary

How does Inhibrx Biosciences compare to Qiagen?

Summary

How does Inhibrx Biosciences compare to Kymera Therapeutics?

Summary

How does Inhibrx Biosciences compare to Arcellx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INBX vs. The Competition

Inhibrx Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inhibrx Biosciences (INBX) Competitors

INBX vs. CYTK, IBRX, QGEN, KYMR, and ACLX

How does Inhibrx Biosciences compare to Cytokinetics?

Summary

How does Inhibrx Biosciences compare to ImmunityBio?

Summary

How does Inhibrx Biosciences compare to Qiagen?

Summary

How does Inhibrx Biosciences compare to Kymera Therapeutics?

Summary

How does Inhibrx Biosciences compare to Arcellx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INBX vs. The Competition

Inhibrx Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools